PCA
XERS icon

Pallas Capital Advisors’s Xeris Biopharma Holdings XERS Stock Holding History

Pallas Capital Advisors’s Portfolio XERS Stock Details XERS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$64.5K Buy
11,121
+118
+1% +$782 ﹤0.01% 818
2025
Q4 		$86.4K Sell
11,003
-24
-0.2% -$189 ﹤0.01% 849
2025
Q3 		$89.8K Buy
11,027
+22
+0.2% +$146 ﹤0.01% 832
2025
Q2 		$51.4K Sell
11,005
-4,338
-28% -$19.9K ﹤0.01% 827
2025
Q1 		$84.2K Buy
+15,343
New +$61.9K ﹤0.01% 712

Other funds holding XERS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return
RA
Rosalind Advisors Toronto, Ontario, Canada $249M AUM 80.12% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Pallas Capital Advisors's XERS Position: Q1 2026 in Review

Pallas Capital Advisors increased its Xeris Biopharma Holdings (XERS) stake by 1.1% in Q1 2026, buying an estimated $782 and bringing the position to 11,121 shares worth $64.5K. The position accounts for ﹤0.01% of the portfolio, ranked #818.

Pallas Capital Advisors first reported a position in XERS in Q1 2025 and has held it in 5 quarters since. The position peaked at $89.8K in Q3 2025. 237 funds tracked by Wall St. Rank hold XERS as of Q1 2026.

  • Pallas Capital Advisors held 11,121 shares of Xeris Biopharma Holdings worth $64.5K as of Q1 2026.
  • Pallas Capital Advisors bought 118 Xeris Biopharma Holdings shares in Q1 2026, an estimated $782.
  • Xeris Biopharma Holdings made up ﹤0.01% of Pallas Capital Advisors's portfolio in Q1 2026, its #818 holding.
  • Pallas Capital Advisors first reported a position in Xeris Biopharma Holdings in Q1 2025 and has held it in 5 quarters since.
  • Pallas Capital Advisors's Xeris Biopharma Holdings position peaked at $89.8K in Q3 2025.
  • 237 funds tracked by Wall St. Rank held Xeris Biopharma Holdings as of Q1 2026.

Based on Pallas Capital Advisors's 13F filing for Q1 2026, filed 21 Apr 2026.